Drug
Octocog Alfa
Octocog Alfa: highest development phase Post-Market, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Octocog alfa (recombinant human coagulation factor VIII) NCT02170402 | Post-Market | Hemophilia A |
Latest
No recent events.
Follow Octocog Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.